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Abstract 
Introduction: Pituitary adenomas constitute one of the most common intracranial tumours. The mouse double minute 2 homologue 
(MDM2) is considered as an important oncogene in many tumours, but it has been little studied in pituitary adenomas and the mecha-
nism is not well understood. The purpose of this study was to investigate the function of MDM2 and its primary mechanism of action 
in pituitary adenoma cells. 
Material and methods: The expression of MDM2 in pituitary adenoma cell lines and normal cells was determined by real-time polymerase 
chain reaction (RT-PCR). The proliferation and apoptosis of pituitary adenoma cells after inhibition of MDM2 expression were detected 
by MTS and flow cytometry, respectively. The protein expressions of MDM2 and p53 were detected by western blot. Co-IP was used to 
detect the direct binding between MDM2 and p53. 
Results: The results of RT-PCR showed that MDM2 was significantly up-regulated in pituitary adenoma cell lines. Inhibition of MDM2 
suppressed the proliferation and promoted apoptosis of pituitary adenoma cells. However, inhibiting the expression of MDM2 can promote 
the protein expression of p53. The results of co-IP showed that MDM2 interacted with p53 by direct combination. Then, we inhibited 
the expressions of p53 and MDM2 simultaneously in the pituitary adenoma cells by co-transfecting siRNAs, and the results showed that, 
compared with the group that inhibited MDM2 alone, cell proliferation of the co-transfected group increased and apoptosis of the co-
transfected group decreased, which was similar to the NC group. 
Conclusions: Taken together, these results suggest that MDM2 promoted the proliferation and inhibited the apoptosis of pituitary adenoma 
cells by directly interacting with p53 in pituitary adenoma cells. Therefore, MDM2-p53 may serve as a novel marker and therapeutic target 
for pituitary adenomas. (Endokrynol Pol 2020; 71 (5): 425–431)
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Introduction
Pituitary adenoma is a common primary brain tumour, 
accounting for about 22.5% of intracranial tumours, 
ranking third in incidence, but only 0.1–0.2% were di-
agnosed as pituitary carcinoma [1, 2]. There are many 
types of pituitary adenomas depending on the hormone 
secretion. In China, 42.70% of pituitary carcinomas did 
not secrete hormones, while the others secreted a vari-
ety of hormones, such as follicle-stimulating hormone, 
prolactin, growth hormone, and adrenocorticotropin 
[3]. Due to the different types of pituitary adenoma, its 
pathogenesis may also be diverse. However, one point is 
recognised: the pathogenesis of pituitary adenoma may 
include the mutation and expression of early genes and 
pituitary-specific oncogenes, which is a complex event 
involving multiple molecules. Therefore, elucidating 
the molecular pathogenesis of pituitary adenoma and 
identifying reliable biomarkers for diagnosis and treat-
ment are still the key points in this field.
The mouse double minute 2 homologue (MDM2) 
gene is an oncogene locating in chromosome 12q13214 
[4]. In many cancers, MDM2 has been proven to be 
an oncogene overexpressed in cancer tissues. For ex-
ample, in malignant pleural mesothelioma, MDM2 is 
a prognostic factor associated with poor survival and 
a predictive marker for a platin pemetrexed therapy [5, 
6]. In breast cancer, MDM2 induces epithelial-to-mes-
enchymal transition (EMT) in vitro and in vivo, and 
the expression of MDM2 can lead to different tumour 
processes in different types of breast cancer [7, 8], while 
in pituitary adenoma, little research has been done on 
MDM2. Suliman et al. first found that MDM2 was ex-
pressed in the cytoplasm of tumours as a downstream 
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trol. We applied 2- Δ Δ CT to calculate the relative expression quantity. 
The primers of MDM2 and GAPDH were listed as follows: MDM2 F: 
5’-AAGATGCGCGGGAAGTAGC-3’, R: 5’-GGTTTTGGTCTAACCT-
GGAGGC-3’; GAPDH F: 5’- TGGCCGTGGGGCTGCCCAG-3’, R: 
5’- GGAAGGCCATGCCAGTGAGC-3’.
Transfection 
The sequences of siRNA were listed: si-MDM2: 5’-GUGU-
GUUAUUAGUUCUUAAAU-3’, si-p53: 5’-ACUACAAGUACAUGU-
GUAAUA-3’ and negative control (NC): 5’-UUCUCCGAACGUGU-
CACGUTT-3’. All of those were purchased from Sigma. Inc. The 
siRNAs were transfected into cells at a concentration of 50 nM by 
lipofectamine transfection reagent (Invi
Cell proliferation assay
Cells (2000 cells/well, three replicates per group) in the 96-well plates 
were cultured for 24, 48, and 72 h, respectively. Cell proliferation 
was determined by MTS using cell proliferation assay kit (Abcam, 
Cambridge, MA, England). 20 µL MTS reagent was added into 
each well and incubated for 4 h at 37°C. After shaking briefly, the 
absorbance of each plate was measured at OD = 490 nm.
Cell apoptosis assay
Cell apoptosis was assayed by Annexin v-FITC Apoptosis De-
tection Kit I (BD Biosciences, Franklin Lakes, NJ, USA). Cell 
culture medium was transferred to 15 ml conical tubes and 
placed on ice. The cells in the 24-well plates were lightly moist-
ened with 2 mL PBS. After removing the PBS, 0.5 ml 0.25% 
trypsin was added to the plates for incubating until cells were 
completely detached from the culture wall. The cells were 
gently suspended in the 1 × binding buffer (0.1 M Hepes/ 
/NaOH pH 7.4, 1.4 M NaCl, 25 mM CaCl2). 0.5 mL of the cell sus-
pension was transferred from the cell culture plate (5 × 105 cells) 
to a clean centrifuge tube. 1.25 µl Annexin v-FITC (BD Biosciences, 
Franklin Lakes, NJ, USA) was added at room temperature (18–24°C) 
in the dark for 15 mins and mixed with 10 µl PI for 5 mins. Samples 
were then diluted with 400 µl 1 × binding buffer and analysed by 
flow cytometry (BD Biosciences, Franklin Lakes, NJ, USA).
Western blot analysis
Lysed cells for 30 mins at 4°C in a buffer containing RIPA (Beyotime, 
Shanghai, China) and then centrifuged at 12,000 rpm for 10 min at 
4°C. Protein concentrations were determined by the Bicinchoninic 
acid (BCA) protein assay kit (Sigma Aldrich Chemical Company, St. 
Louis, MO, USA). For electrophoresis, 30 µg total protein was added 
to every lane, which was separated in Sodium dodecyl sulphate 
polyacrylamide (SDS-PAGE, separate gel 10%, concentrate gel 
6%) gel and then transferred to a polyvinylidene fluoride (PVDF) 
membrane. Then, after blocking the membranes for 2 h at room 
temperature, the membranes were incubated with anti-MDM2 
(Abcam, Cambridge, MA, England, ab226939), anti-p53 (Abcam, 
Cambridge, MA, England, ab131442), or anti-GAPDH (Abcam, 
Cambridge, MA, England, ab8245) overnight. Bands visualisa-
tion was carried out by enhanced chemical luminescence reagent 
(PerkinElmer Life Sciences, MA, USA) after secondary antibody 
(Invitrogen) conjugated Horseradish peroxidase (HRP) incubation. 
The density ratios of MDM2/GAPDH and p53/GAPDH were the 
relative levels of MDM2 and p53.
Co-immunoprecipitation (co-IP) assay
Total protein was extracted from cells — 800 µg total protein, 
incubated at 4°C overnight with anti-MDM2 (Abcam, Cambridge, 
MA, England, ab226939). Then, protein A agarose beads (20 µL) 
were mixed and incubated for 2 h. The mixture above was then 
centrifuged and washed three times with PBS. Western blotting 
was performed to detect p53 protein of precipitation.
gene of p53, indicating that MDM2 may be a functional 
factor in pituitary adenoma [9]. Furthermore, Yao X et 
al. found that MDM2 may be a biomarker and potential 
drug target for pituitary adenoma treatment [10]. How-
ever, the mechanism of MDM2 in pituitary adenoma 
has not been studied thoroughly and clearly.
At present, the mechanism of MDM2 acting as 
a proto-oncogene in tumourigenesis is mainly fo-
cused on its binding with p53 gene, which are often 
inseparable from each other. P53 and MDM2 regulate 
p53 protein activity and MDM2 gene expression by 
forming a self-regulating negative feedback loop 
[11]. In many cancers, the negative feedback loop of 
MDM2-p53 plays an important regulatory role. Disrup-
tion of the MDM2-p53 loop function by introducing 
molecule could suppress hepatocellular carcinoma 
tumourigenesis [12]. A small molecule inhibitor of 
MDM2-p53 could enhance the radio-sensitivity of 
gastric adenocarcinoma [13]. Similarly, another inhibi-
tor of MDM2-p53 could suppress cell proliferation in 
nasopharyngeal carcinoma [14]. However, the function 
and mechanism of MDM2-p53 negative feedback loop 
in pituitary adenoma have not been reported before. 
Therefore, on the basis of the above, our study con-
ducted a detailed study on the expression and function 
of MDM2 in pituitary adenoma cells. In addition, the 
mechanism of MDM2’s influence on pituitary adenoma 
cells through directly binding p53 was also verified. Our 
study provided a research basis for MDM2 as a possible 
therapeutic target of pituitary adenoma. 
Material and methods 
Cell lines
Mouse pituitary adenoma cell lines AtT-20 (CCL-89) was purchased 
from the American type culture collection (ATCC, USA) which has 
adrenocorticotropic hormone (ACTH) activity. Mouse pituitary 
adenoma cell lines GT1-1 was purchased from China Academy 
of Medical Sciences Cell Resource Centre, which has luteinising 
hormone-releasing hormone (LHRH) activity. Mouse pituitary 
cell MPC was purchased from ScienCell (USA). MPC and GT1-1 
cells were cultured in high-glucose Dulbecco’s modified eagle’s 
medium (DMEM, Gibco, Life Technologies, Gaithersburg, MD, 
USA) supplemented with 10% horse serum (Gibco, Life Technolo-
gies, Gaithersburg, MD, USA) and 2.5% foetal bovine serum (FBS, 
Gibco, Life Technologies, Gaithersburg, MD, USA). AtT-20 cells were 
cultured in F-12K medium (Gibco, Life Technologies, Gaithersburg, 
MD, USA) supplemented with 10% horse serum (Gibco, Life 
Technologies, Gaithersburg, MD, USA) and 2.5% FBS (Gibco, Life 
Technologies, Gaithersburg, MD, USA). All of them were incubated 
at 37°C in a humidified atmosphere with 5% CO2. 
RT-qPCR
We extracted total RNAs of cell lines according to the RNeasy 
kit (Qiagen, Inc., Valencia, CA, USA) instructions. The reverse 
transcription was reacted using the One step cDNA synthesis kit 
(Takara). Quantitative real-time PCR (RT-qPCR) was performed on 
the ABI7500 real-time PCR system (Applied Biosystems) using the 
SYBR® premix kit (Takara). GAPDH was used as the internal con-
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All experimental data were analysed using SPSS 17.0 (SPSS Inc., 
Chicago, IL, USA). All the final results were presented as mean 
± standard deviation. Student’s t-test was used to determine the 
differences between two groups. p < 0.05 was considered as the 
level of statistical significance.
Results
MDM2 was up-regulated in pituitary adenoma 
cell lines
In order to determine whether MDM2 was differentially 
expressed in pituitary adenomas cell lines, pituitary cell 
MPC, pituitary adenoma cancer cells GT1-1 and AtT-20 
were analysed by the RT-PCR. The result showed that 
the expression of MDM2 was significantly increased 
in pituitary adenoma cells in comparison with MPC 
cells (Fig. 1).
MDM2 inhibition suppressed proliferation 
of pituitary adenomas cell lines
To evaluate the function of MDM2 in pituitary 
adenoma cells, the expression of MDM2 was decreased 
by transfecting siRNA of MDM2 into both AtT-20 and 
GT1-1 cells. The expression of MDM2 was confirmed 
by western blot. As shown in Figure 2A MTS was used 
to investigate the proliferation of pituitary adenomas 
cells. Inhibition of MDM2 significantly decreased the 
proliferation of pituitary adenoma cells as compared 
to the negative control (Fig. 2B). 
MDM2 inhibition promoted apoptosis 
of pituitary adenoma cell lines
Flow cytometry was used to further investigate the 
apoptosis of all the groups. Inhibition of MDM2 
significantly promoted the apoptosis of pituitary ad-
enoma cells as compared to the negative control (Fig. 3) 
(p < 0.05). These results suggest that MDM2 could 
promote the vitality of AtT-20 and GT1-1 cells.
MDM2 negatively regulated p53 through direct 
binding in pituitary adenoma cell lines
In order to verify the relationship between MDM2 and 
p53 in pituitary adenoma cells, we firstly examined the 
p53 protein level when transfecting siRNA of MDM2 
in AtT-20 and GT1-1 cells. The results of western blot 
showed that the protein level of p53 was increased 
when MDM2 protein expression was decreased by 
siRNA (Fig. 4A). Furthermore, we used a co-IP experi-
ment to detect whether MDM2 directly binds to p53 
in pituitary adenoma cells. The precipitation pulled 
down by MDM2 antibody was analysed by western 
blot; positive p53 protein was shown in both AtT-20 



























Figure 1. The mouse double minute 2 homologue (MDM2) 
was up-regulated in pituitary adenoma cell lines. Real-time 
quantitative polymerase chain reaction (RT-qPCR) was performed 
to evaluate the expression of MDM2 in pituitary adenomas cell 
lines and normal cell lines (*p < 0.05)
A
B
Figure 2. Inhibition of the mouse double minute 2 homologue (MDM2) suppressed the proliferation of pituitary adenomas cells. 
A. Western blot was used to detect the protein level of MDM2 when the si-MDM2 and its NC were transfected into AtT-20 and GT1-1 
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MDM2 directly interacts with p53 in pituitary ad-
enoma cells.
P53 inhibition could counteract the effect 
on proliferation and apoptosis of pituitary 
adenoma cells induced by MDM2 inhibition
To further verify the effect of this direct correlation 
between MDM2 and p53 on pituitary adenoma cells, 
we co-transfected siRNA of MDM2 and siRNA of p53 
into pituitary adenomas cells. Western blot was used 
to detect the protein level of MDM2 and p53 using 
GAPDH as internal parameters. MTS assay was used 
to detect the cell proliferation of each group, and flow 
cytometry was used to detect cell apoptosis. The re-
sults showed that p53 expression was decreased upon 
co-transfection of two siRNAs (Fig. 5A), while the pro-
liferation (Fig. 5B) was enhanced and the apoptosis (Fig. 
5C) was decreased comparing to the group of si-MDM2 
alone. These results suggest that the inhibition of p53 
in pituitary adenomas cells could offset the affection 
on proliferation and apoptosis caused by the inhibition 
of MDM2.
Discussion
The mouse double minute 2 homologue was first 
cloned from the double-minute chromosome of 
spontaneously transformed mouse cell lines [15]. The 
mouse double minute 2 homologue was subsequently 
shown to have oncogenic functions and to be involved 
in tumourigenesis [16, 17]. In pituitary adenomas, Suli-
man et al. first found that MDM2 may be a functional 
factor in pituitary adenoma [9]. Furthermore, Yao 
X et al. found that MDM2 may be a biomarker and 
potential drug target for non-functioning pituitary 
adenoma treatment [10]. However, there has been 
no in-depth study on the effect of MDM2 in pituitary 
adenoma cells. 
Figure 3. Inhibition of the mouse double minute 2 homologue (MDM2) promoted the apoptosis of pituitary adenomas cells. Cell apoptosis 
was detected by flow cytometry when the si-MDM2 and its NC were transfected into AtT-20 and GT1-1 cells, respectively (*p < 0.05)
A
B
Figure 4. The mouse double minute 2 homologue (MDM2) negatively regulated p53 through direct binding in pituitary adenomas cell 
lines. A. The protein level of p53 was detected when the expression of MDM2 was inhibited. B. The direct binding between MDM2 and 
p53 was array by Co-IP. The precipitation pulled down by MDM2 antibody was analysis by western blot using anti-p53
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Our study examined the expression of MDM2 in 
pituitary adenoma cells and confirmed that MDM2 was 
highly expressed in pituitary adenoma cells compared 
with normal cells. Moreover, after interfering with the 
expression of MDM2, the proliferation ability of pitu-
itary adenoma cells was inhibited and apoptosis was 
promoted. This suggests that MDM2 also plays a role 
as a proto-oncogene in pituitary adenoma cells and is 
involved in tumourigenesis.
P53 is a powerful tumour suppressor, and more than 
half of human tumours have p53 mutations [18]. The 
MDM2 gene regulated the activity of p53 protein by 
binding to the N-terminus of p53 [19]. P53 and MDM2 
always form a self-regulating negative feedback loop 
to regulate cell function [11]. When MDM2 expression 
decreases, p53 expression increases, which binds to 
the P2 promoter of MDM2 to induce MDM2 expres-
sion in turn [20]. MDM2-p53 has been reported to play 
key roles in tumour suppressive [21]. In our study, we 
found that higher expression of MDM2 could directly 
bind to p53 protein in pituitary adenoma cells, and that 
interfering with the expression of p53 could counteract 
the proliferation inhibition and apoptosis promotion of 
cancer cells caused by the inhibition of MDM2. It has 
been suggested that MDM2-p53 plays an important 
regulatory role in pituitary adenoma because it does 
so in other tumours. 
Based on our studies and existing reports, it can be 
seen that MDM2 is highly expressed in pituitary adeno-
ma, and p53 is still an important link in its mechanism. 
Also, MDM2-p53 is an important pathway affecting 
the occurrence of pituitary adenoma. Hence, it is easy 
to conclude that targeting the MDM2-p53 negative 
feedback loop would be a good strategy for pituitary 
adenoma treatment. 
In fact, a number of compounds or small molecules 
targeting MDM2-p53 have been used by researchers to 
test the efficacy of treatments in different cancers. Be-
cause overexpression of MDM2 reduces the ability of 
p53, MDM2 inhibitors have been used to activate p53 
activity for cancer therapy in recent years [22]. Vassilev et 
al. first reported Nutlins as a small-molecule inhibitor of 
MDM2, which could induce p53 accumulation and pro-
mote apoptosis of tumour cells [23]. The MDM2 inhibitor 
RG7112 discovered by scientists of the Roche company 
has advanced to clinical trials [24]. Other MDM2 inhibi-
tors, such as SAR405838, MK-8242, NVP-CGM097, and 
AMG232, have also been studied in clinical trials [25–2
Figure 5. P53 inhibition could counteract the effect on proliferation and apoptosis of pituitary adenoma cells induced by the mouse 
double minute 2 homologue (MDM2) inhibition. We co-transfected si-MDM2 with si-p53 or its NC control into pituitary adenoma 
cells. A. Western blot assay was performed to detect the MDM2 and p53 expression on AtT-20 cells and GT1-1 cells, using GAPDH as 
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Conclusions
Our results found that the negative feedback loop of 
MDM2-p53 might still play an important role in pitu-
itary adenoma, which indicates that the small molecule 
inhibitors reported previously have the same anticancer 
effect on pituitary adenoma. This provided a feasible 
strategy for the target treatment of pituitary adenoma. 
This study has limitations because we only detected 
the direct binding between MDM2 and p53 in pituitary 
adenoma. Other mechanisms, such as MDM2, which 
acts as an E3 ubiquitin ligase to promote p53 degrada-
tion, MDM2, which promotes p53 to transfer from 
nuclear to cytoplasmic, and p53, which regulates the 
expression of MDM2 and other downstream factors 
as a transcription factor, all need further research. In 
general, a detailed study on the regulation mechanism 
of MDM2 through p53 in pituitary adenoma cells can 
provide new strategies for the treatment of pituitary 
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